(SNT) Synektik S.A. - Ratings and Ratios
Radiology, Cardiology, Nuclear, Imaging, Software
SNT EPS (Earnings per Share)
SNT Revenue
Description: SNT Synektik S.A.
Synektik S.A. (WAR:SNT) is a Polish healthcare equipment company with a market capitalization of approximately 1.77 billion PLN. The companys stock has demonstrated a relatively stable performance, with a beta of 0.875, indicating lower volatility compared to the overall market.
From a fundamental analysis perspective, Synektik S.A. exhibits a promising return on equity (RoE) of 49.44%, suggesting effective management and a strong ability to generate profits from shareholder equity. The price-to-earnings (P/E) ratio stands at 19.08, while the forward P/E is 14.53, indicating potential for future earnings growth. These metrics imply that the company is undervalued relative to its expected future performance.
Key economic drivers for Synektik S.A. likely include the growing demand for healthcare equipment in Poland and the broader European region. The companys position within the healthcare equipment sub-industry, which is often characterized by steady demand and limited cyclical fluctuations, may provide a relatively stable source of revenue. Additionally, Synektik S.A.s ability to maintain a strong RoE and potentially expand its market share could be driven by factors such as innovative product offerings, strategic partnerships, or effective cost management.
To further evaluate Synektik S.A.s investment potential, it is essential to monitor key performance indicators (KPIs) such as revenue growth, gross margin, and operating cash flow. Analyzing these metrics in conjunction with the companys valuation multiples and return on equity will provide a more comprehensive understanding of its financial health and growth prospects.
SNT Stock Overview
| Market Cap in USD | 553m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception |
SNT Stock Ratings
| Growth Rating | 87.0% |
| Fundamental | 79.6% |
| Dividend Rating | 82.9% |
| Return 12m vs S&P 500 | 19.7% |
| Analyst Rating | - |
SNT Dividends
| Dividend Yield 12m | 3.66% |
| Yield on Cost 5y | 38.46% |
| Annual Growth 5y | 53.12% |
| Payout Consistency | 96.4% |
| Payout Ratio | 70.6% |
SNT Growth Ratios
| Growth Correlation 3m | 81% |
| Growth Correlation 12m | 66.2% |
| Growth Correlation 5y | 90% |
| CAGR 5y | 114.68% |
| CAGR/Max DD 3y | 4.65 |
| CAGR/Mean DD 3y | 19.22 |
| Sharpe Ratio 12m | 1.55 |
| Alpha | 0.04 |
| Beta | 0.977 |
| Volatility | 30.89% |
| Current Volume | 19k |
| Average Volume 20d | 18.5k |
| Stop Loss | 233.5 (-3.5%) |
| Signal | 0.81 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (99.9m TTM) > 0 and > 6% of Revenue (6% = 37.4m TTM) |
| FCFTA 0.08 (>2.0%) and ΔFCFTA -18.23pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 14.40% (prev 10.65%; Δ 3.75pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.16 (>3.0%) and CFO 64.3m <= Net Income 99.9m (YES >=105%, WARN >=100%) |
| Net Debt (-39.6m) to EBITDA (101.5m) ratio: -0.39 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.58 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (8.53m) change vs 12m ago 0.0% (target <= -2.0% for YES) |
| Gross Margin 34.48% (prev 30.13%; Δ 4.35pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 166.4% (prev 176.5%; Δ -10.08pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 63.60 (EBITDA TTM 101.5m / Interest Expense TTM 1.60m) >= 6 (WARN >= 3) |
Altman Z'' 4.87
| (A) 0.22 = (Total Current Assets 243.5m - Total Current Liabilities 153.7m) / Total Assets 399.3m |
| (B) 0.30 = Retained Earnings (Balance) 119.5m / Total Assets 399.3m |
| (C) 0.27 = EBIT TTM 101.5m / Avg Total Assets 374.9m |
| (D) 0.57 = Book Value of Equity 119.5m / Total Liabilities 208.1m |
| Total Rating: 4.87 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 79.55
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 1.67% = 0.84 |
| 3. FCF Margin 5.25% = 1.31 |
| 4. Debt/Equity 0.03 = 2.50 |
| 5. Debt/Ebitda 0.06 = 2.50 |
| 6. ROIC - WACC (= 31.46)% = 12.50 |
| 7. RoE 51.78% = 2.50 |
| 8. Rev. Trend 50.90% = 3.82 |
| 9. EPS Trend 61.81% = 3.09 |
What is the price of SNT shares?
Over the past week, the price has changed by +4.76%, over one month by +11.01%, over three months by +15.46% and over the past year by +41.84%.
Is Synektik S.A. a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SNT is around 315.33 PLN . This means that SNT is currently undervalued and has a potential upside of +30.3% (Margin of Safety).
Is SNT a buy, sell or hold?
What are the forecasts/targets for the SNT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 255.4 | 5.5% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 355 | 46.7% |
SNT Fundamental Data Overview
Market Cap PLN = 2.00b (2.00b PLN * 1.0 PLN.PLN)
CCE Cash And Equivalents = 45.4m PLN (Cash only, last quarter)
P/E Trailing = 21.5455
P/E Forward = 14.5349
P/S = 3.2052
P/B = 10.4462
Beta = 0.925
Revenue TTM = 623.9m PLN
EBIT TTM = 101.5m PLN
EBITDA TTM = 101.5m PLN
Long Term Debt = 3.89m PLN (from longTermDebt, last quarter)
Short Term Debt = 1.90m PLN (from shortLongTermDebt, last quarter)
Debt = 5.79m PLN (Calculated: Short Term 1.90m + Long Term 3.89m)
Net Debt = -39.6m PLN (calculated as Total Debt 5.79m - CCE 45.4m)
Enterprise Value = 1.96b PLN (2.00b + Debt 5.79m - CCE 45.4m)
Interest Coverage Ratio = 63.60 (Ebit TTM 101.5m / Interest Expense TTM 1.60m)
FCF Yield = 1.67% (FCF TTM 32.7m / Enterprise Value 1.96b)
FCF Margin = 5.25% (FCF TTM 32.7m / Revenue TTM 623.9m)
Net Margin = 16.01% (Net Income TTM 99.9m / Revenue TTM 623.9m)
Gross Margin = 34.48% ((Revenue TTM 623.9m - Cost of Revenue TTM 408.8m) / Revenue TTM)
Tobins Q-Ratio = 16.39 (Enterprise Value 1.96b / Book Value Of Equity 119.5m)
Interest Expense / Debt = 3.82% (Interest Expense 221.1k / Debt 5.79m)
Taxrate = 20.54% (21.3m / 103.9m)
NOPAT = 80.6m (EBIT 101.5m * (1 - 20.54%))
Current Ratio = 1.58 (Total Current Assets 243.5m / Total Current Liabilities 153.7m)
Debt / Equity = 0.03 (Debt 5.79m / last Quarter total Stockholder Equity 191.2m)
Debt / EBITDA = 0.06 (Net Debt -39.6m / EBITDA 101.5m)
Debt / FCF = 0.18 (Debt 5.79m / FCF TTM 32.7m)
Total Stockholder Equity = 192.9m (last 4 quarters mean)
RoA = 25.01% (Net Income 99.9m, Total Assets 399.3m )
RoE = 51.78% (Net Income TTM 99.9m / Total Stockholder Equity 192.9m)
RoCE = 51.57% (Ebit 101.5m / (Equity 192.9m + L.T.Debt 3.89m))
RoIC = 41.07% (NOPAT 80.6m / Invested Capital 196.3m)
WACC = 9.60% (E(2.00b)/V(2.00b) * Re(9.62%)) + (D(5.79m)/V(2.00b) * Rd(3.82%) * (1-Tc(0.21)))
Discount Rate = 9.62% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 63.68% ; FCFE base≈56.7m ; Y1≈37.2m ; Y5≈17.0m
Fair Price DCF = 30.81 (DCF Value 262.8m / Shares Outstanding 8.53m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 61.81 | EPS CAGR: 84.95% | SUE: N/A | # QB: 0
Revenue Correlation: 50.90 | Revenue CAGR: 42.37% | SUE: 0.28 | # QB: 0